When Prevention Fails: Obesity Treatment Strategies

被引:26
作者
Aronne, Louis J. [1 ,2 ]
Wadden, Thomas [3 ,4 ]
Isoldi, Kathy Keenan [5 ]
Woodworth, Kristina A. [6 ]
机构
[1] New York Presbyterian Hosp, Comprehens Weight Control Program, Weill Cornell Med Coll, New York, NY 10028 USA
[2] Weill Cornell Med Coll, Dept Med, New York, NY USA
[3] Univ Penn, Dept Psychol, Sch Med, Philadelphia, PA 19104 USA
[4] Univ Penn, Ctr Weight & Eating Disorders, Philadelphia, PA 19104 USA
[5] New York Presbyterian Hosp, Comprehens Weight Control Program, Clin Nutr Serv, New York, NY 10028 USA
[6] SciMantis Commun Inc, Pen Argyl, PA USA
关键词
Exercise; Diet and lifestyle intervention; Obesity treatment; Pharmacotherapy; Weight loss; LIFE-STYLE MODIFICATION; CANNABINOID-1 RECEPTOR BLOCKER; CARDIOVASCULAR RISK-FACTORS; TERM DIETARY INTERVENTION; LOW-CALORIE DIET; WEIGHT-LOSS; PHARMACOLOGICAL-TREATMENT; OVERWEIGHT PATIENTS; DOUBLE-BLIND; RIMONABANT;
D O I
10.1016/j.amjmed.2009.01.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The obesity epidemic has resulted in increasingly urgent calls for large-scale prevention strategies. Meanwhile, effective treatment approaches that result in sustainable weight loss are needed to attenuate the cardiometabolic risks that may lead to comorbid illnesses and early mortality. Public education efforts geared toward those afflicted with obesity should emphasize that a relatively modest reduction in body weight dramatically reduces disease risk, thereby improving overall long-term health. Setting realistic weight loss goals with patients should reduce the overwhelming frustration often associated with the belief that large amounts of weight loss are needed for improved health. This misconception often impedes overweight and obese individuals from seeking treatment. Effective strategies are available to help overweight and obese individuals achieve reasonable weight loss goals. Important challenges exist in preventing weight regain following weight loss intervention. Studies are underway to identify new therapeutic strategies to effectively reduce weight, as well as to provide long-term data on successful weight loss maintenance strategies. (C) 2009 Published by Elsevier Inc. The American Journal of Medicine (2009) 122, S24-S32
引用
收藏
页码:S24 / S32
页数:9
相关论文
共 50 条
  • [1] [Anonymous], NIH PUBL
  • [2] [Anonymous], 2000, PRACTICAL GUIDE IDEN
  • [3] [Anonymous], 2005, IDF CONS WORLDW DEF
  • [4] [Anonymous], 2005, Dietary guidelines for Americans
  • [5] Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine
    Apfelbaum, M
    Vague, P
    Ziegler, O
    Hanotin, C
    Thomas, F
    Leutenegger, E
    [J]. AMERICAN JOURNAL OF MEDICINE, 1999, 106 (02) : 179 - 184
  • [6] Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes
    Brancati, F
    Charleston, J
    Cheskin, L
    Clark, J
    DiGregorio-Celnik, D
    Friedman-Donze, L
    Rubin, R
    Stewart, K
    Bray, GA
    DeLee, DG
    Boss, KR
    Greenway, FL
    Lovejoy, JC
    Ryan, DH
    Williamson, DA
    West, DS
    DiLillo, V
    Raczynski, JM
    Lewis, CE
    Oberman, A
    Thomas, S
    Nathan, DM
    Horton, ES
    Turgeon, H
    Jackson, SD
    Blackburn, GL
    Delahanty, L
    Steiner, B
    Cagliero, E
    Mantzoros, C
    Hill, JO
    Phillipp, J
    Hamman, RF
    Schwartz, R
    Regensteiner, J
    Van Dorsten, B
    McDermott, MT
    Dills, DG
    Foreyt, JP
    Reeves, RS
    Pownell, HJ
    Balasubramanyam, A
    Jones, PH
    Saad, MF
    Jinagouda, S
    Chiu, K
    Morales, L
    Ghazarian, S
    Navarrete, G
    Iqbal, N
    [J]. CONTROLLED CLINICAL TRIALS, 2003, 24 (05): : 610 - 628
  • [7] Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
    Buse, John B.
    Klonoff, David C.
    Nielsen, Loretta L.
    Guan, Xuesong
    Bowlus, Christopher L.
    Holcombe, John H.
    Maggs, David G.
    Wintle, Matthew E.
    [J]. CLINICAL THERAPEUTICS, 2007, 29 (01) : 139 - 153
  • [8] Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide
    Cani, PD
    Montoya, ML
    Neyrinck, AM
    Delzenne, NM
    Lambert, DM
    [J]. BRITISH JOURNAL OF NUTRITION, 2004, 92 (05) : 757 - 761
  • [9] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [10] Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725